دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial.
Stinchcombe, Thomas E. MD 1,2,
doi : 10.1200/JCO.22.02660
Volume 41(6) pgs. 1159-1327 February 20, 2023
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Fukuoka, Masahiro; Yano, Seiji; Giaccone, Giuseppe; Tamura, Tomohide; Nakagawa, Kazuhiko; Douillard, Jean-Yves; Nishiwaki, Yutaka; Vansteenkiste, Johan; Kudoh, Shinzoh; Rischin, Danny; Eek, Richard; Horai, Takeshi; Noda, Kazumasa; Takata, Ichiro; Smit, Egbert; Averbuch, Steven; Macleod, Angela; Feyereislova, Andrea; Dong, Rui-Ping; Baselga, Jose[Combining Acute Accent]
doi : 10.1200/JCO.22.02499
To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).
JCO Flashback: Assessing the Effectivity of Gefitinib in Treating Advanced NSCLC (2003).
doi : 10.1200/JCO.23.00068
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?.
Li, Ziming MD 1,; Lu, Shun MD 1,
doi : 10.1200/JCO.22.02278
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?.
Remon, Jordi MD, PhD 1,; Hendriks, Lizza E.L. MD, PhD 2,; Reck, Martin MD 3,
doi : 10.1200/JCO.22.01737
Trends in Anal Cancer: Leveraging Public Health Efforts to Improve Cancer Care.
Hotca, Alexandra MD 1; Goodman, Karyn A. MD, MS 1,
doi : 10.1200/JCO.22.02584
Reirradiation for Recurrent Glioblastoma: What We Know and What We Do Not.
Knisely, Jonathan P.S. MD 1,; Fine, Howard A. MD 2,3,
doi : 10.1200/JCO.22.01785
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Beyond the Fight: Why President Biden's Cancer Moonshot Must Include Palliative Care.
Daubman, Bethany-Rose MD 1,2,; Rosenberg, Leah B. MD 1,2; Meier, Diane E. MD 3
doi : 10.1200/JCO.22.00838
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Brockelmann, Paul J. MD 1,; Buhnen, Ina MA 1; Meissner, Julia MD 2; Trautmann-Grill, Karolin MD 3,; Herhaus, Peter MD 4,; Halbsguth, Teresa V. MD 5; Schaub, Valdete MD 6; Kerkhoff, Andrea MD 7,; Mathas, Stephan MD 8; Bormann, Matthias MD 9; Dickhut, Andreas MD 10; Kaul, Helen Dipl-Math 1; Fuchs, Michael MD 1,; Kobe, Carsten MD 11; Baues, Christian MD 12; Borchmann, Peter MD 1,; Engert, Andreas MD 1,; von Tresckow, Bastian MD 1,13,
doi : 10.1200/JCO.22.02355
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Brahmer, Julie R. MD 1,,; Lee, Jong-Seok MD, PhD 2; Ciuleanu, Tudor-Eliade MD, PhD 3; Bernabe Caro, Reyes MD, PhD 4,; Nishio, Makoto MD, PhD 5,; Urban, Laszlo MD 6; Audigier-Valette, Clarisse MD 7; Lupinacci, Lorena MD 8; Sangha, Randeep MD 9,; Pluzanski, Adam MD, PhD 10,; Burgers, Jacobus MD, PhD 11,; Mahave, Mauricio MD 12; Ahmed, Samreen MD 13; Schoenfeld, Adam J. MD 14,; Paz-Ares, Luis G. MD, PhD 15,; Reck, Martin MD, PhD 16,; Borghaei, Hossein DO, MS 17,; O'Byrne, Kenneth J. MD, PhD 18,; Gupta, Ravi G. MD 19,; Bushong, Judith BS 19,; Li, Li MS, DPH 19,; Blum, Steven I. MBA 19,; Eccles, Laura J. PhD 19,; Ramalingam, Suresh S. MD 20,
doi : 10.1200/JCO.22.01503
We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson, Melissa L. MD 1,,; Cho, Byoung Chul MD, PhD 2,; Luft, Alexander MD 3; Alatorre-Alexander, Jorge MD 4; Geater, Sarayut Lucien MD 5,; Laktionov, Konstantin MD 6; Kim, Sang-We MD, PhD 7; Ursol, Grygorii MD 8; Hussein, Maen MD 9,; Lim, Farah Louise MBBS, MRCP 10; Yang, Cheng-Ta MD 11; Araujo, Luiz Henrique MD, PhD 12,; Saito, Haruhiro MD, PhD 13,; Reinmuth, Niels MD, PhD 14,; Shi, Xiaojin MD 15,; Poole, Lynne MSc 16,; Peters, Solange MD, PhD 17,; Garon, Edward B. MD 18,; Mok, Tony MD 19,; for the POSEIDON investigators
doi : 10.1200/JCO.22.00975
The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC).
State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States.
Damgacioglu, Haluk PhD 1; Lin, Yueh-Yun MS 1; Ortiz, Ana Patricia PhD, MPH 2,; Wu, Chi-Fang PhD 3; Shahmoradi, Zahed PhD 1; Shyu, Shiang Shiuan MS 1,4; Li, Ruosha PhD 4; Nyitray, Alan G. PhD 5,6,; Sigel, Keith MD, PhD, MPH 7,; Clifford, Gary M. PhD 8; Jay, Naomi NP, PhD 9,; Lopez, Vivian Colon PhD 2,; Barnell, Gregory M. NP, MS 10; Chiao, Elizabeth Y. MD, MPH 11; Stier, Elizabeth A. MD 12; Ortiz-Ortiz, Karen J. DrPH 2,; Ramos-Cartagena, Jeslie M. MS 13; Sonawane, Kalyani PhD 14,15,; Deshmukh, Ashish A. PhD, MPH 14,15,,
doi : 10.1200/JCO.22.01390
Squamous cell carcinoma of the anus (SCCA) incidence and mortality rates are rising in the United States. Understanding state-level incidence and mortality patterns and associations with smoking and AIDS prevalence (key risk factors) could help unravel disparities and provide etiologic clues.
Medicare Advantage: A Disadvantage for Complex Cancer Surgery Patients.
Raoof, Mustafa MD, MS 1,,; Ituarte, Philip H.G. PhD 1; Haye, Sidra PhD 2; Jacobson, Gretchen PhD 3; Sullivan, Kevin M. MD 1; Eng, Oliver MD 4,; Kim, Jae MD 1,; Fong, Yuman MD 1,
doi : 10.1200/JCO.21.01359
Nearly half of all Medicare beneficiaries are enrolled in privatized Medicare insurance plans (Medicare Advantage [MA]). Little comparative information is available about access, outcomes, and cost of inpatient cancer surgery between MA and Traditional Medicare (TM) beneficiaries.
Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial.
Behroozian, Tara MD(C) 1; Milton, Lauren BSc(C) 1; Karam, Irene MD 1,; Zhang, Liying PhD 2; Ding, Keyue PhD 3; Lou, Julia BSc(C) 4; Gallant, Francois MRT(T) 1; Rakovitch, Eileen MD MSc 1,; Tran, William PhD, MRT(T) 1; Soliman, Hany MD 1; Leung, Eric MD, MSc 1; Vesprini, Danny MD, MSc 1,; Szumacher, Ewa MD 1; Chen, Hanbo MD 1,; Donovan, Elysia MD MSc 4; Lam, Jacqueline MD 5,6; Spadafora, Silvana MD 6; Wronski, Matt PhD 1; Lavoie, Chris RPN 5,; Walde, Natalie BSc, CCRP 6; Lam, Emily BScPA(C) 1; Wong, Gina BSc 1,; McKenzie, Erin BSc 1; Ariello, Krista MD(C), MSc 1; Kennedy, Samantha BSc(C) 1; Shariati, Saba BSc(C) 1; Carothers, Katherine RN, MN, CON(C) 1,; Gonzales, Glen MRT(T) 1; Kagan, Yulya RN 1; Chow, Edward MBBS 1,
doi : 10.1200/JCO.22.01873
Radiation dermatitis (RD) is common in patients undergoing breast radiotherapy. Mepitel film (MF) can reduce RD, but the results from two randomized controlled trials are conflicting.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin, Thomas MD 1,; Usmani, Saad Z. MD 2,; Berdeja, Jesus G. MD 3,; Agha, Mounzer MD 4,; Cohen, Adam D. MD 5,; Hari, Parameswaran MD 6,; Avigan, David MD 7,; Deol, Abhinav MD 8,; Htut, Myo MD 9,; Lesokhin, Alexander MD 2,; Munshi, Nikhil C. MD 10,11,; O'Donnell, Elizabeth MD 12,; Stewart, A. Keith MBChB 13,; Schecter, Jordan M. MD 14,; Goldberg, Jenna D. MD 14,; Jackson, Carolyn C. MD, MPH 14,; Yeh, Tzu-Min MS 14,; Banerjee, Arnob MD 15,; Allred, Alicia PhD 15,; Zudaire, Enrique PhD 15,; Deraedt, William MSc 16,; Olyslager, Yunsi MSc 16; Zhou, Changwei PhD 17,; Pacaud, Lida MD 17,; Madduri, Deepu MD 14,; Jakubowiak, Andrzej MD 18,; Lin, Yi MD, PhD 19,; Jagannath, Sundar MD 20,,
doi : 10.1200/JCO.22.00842
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi, Jian-Qing MD, PhD 1; Zhao, Wanhong MD, PhD 2; Jing, Hongmei MD, PhD 3; Fu, Weijun MD, PhD 4; Hu, Jianda MD, PhD 5; Chen, Lijuan MD, PhD 6; Zhang, Yiwen MD, PhD 7,; Yao, Dan PhD 8; Chen, Diana MS 8,; Schecter, Jordan M. MD 9,; Yang, Fan MD, PhD 8,; Tian, Xiaochen PhD 8,; Sun, Huabin MD, MS 9,; Zhuang, Sen Hong MD, PhD 8,; Ren, Jimmy PhD 8,; Fan, Xiaohu MD, PhD 7,; Jin, Jie MD, PhD 10; Niu, Ting MD, PhD 11; Chen, Sai-Juan MD, PhD 1,
doi : 10.1200/JCO.22.00690
CARTIFAN-1 aimed to evaluate the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (RRMM).
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien, Christina I. MD 1,,; Pugh, Stephanie L. PhD 2,; Dicker, Adam P. MD, PhD 3,; Raizer, Jeffrey J. MD 4,; Matuszak, Martha M. PhD 5,; Lallana, Enrico C. MD 6,; Huang, Jiayi MD 7,; Algan, Ozer MD 8; Deb, Nimisha MD 9; Portelance, Lorraine MD 10,; Villano, John L. MD, PhD 11; Hamm, John T. MD 12,; Oh, Kevin S. MD 13; Ali, Arif N. MD 14,; Kim, Michelle M. MD 15,; Lindhorst, Scott M. MD 16; Mehta, Minesh P. MD 17,
doi : 10.1200/JCO.22.00164
To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM).
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules.
Xu, Huixiong MD 1,2,3; Zhang, Yifeng MD 1,2; Wu, Hongxun MD 4; Zhou, Ning PhD, MBA 5,; Li, Xing PhD 5,; Pineda, John P. MS 5,; Zhu, Yun MD 4; Fu, Huijun MD 2,6; Ying, Ming MD 7; Yang, Shufang MD 7,8; Bao, Jiandong MD 4; Yang, Lulu MD 9; Zhang, Bingjie MD 4; Guo, Lehang MD 1,2; Sun, Liping MD 1,2; Lu, Feng MD 1,2; Wang, Hanxiang MD 1,2; Huang, Ying MD 10; Zhu, Tiantong MD 10; Wang, Xiaonan MS 5,; Wei, Qing MD 2,6; Sheng, Chunjun MD 2,11; Qu, Shen MD 2,11; Lv, Zhongwei MD 2,12; Xu, Dong MD 13; Li, Qian MD 14; Dong, Yongling MD 14; Qin, Jianwu MD 15; Cheng, Tong MD 5,; Xing, Mingzhao MD, PhD 16,,
doi : 10.1200/JCO.22.00232
To explore the novel diagnostic value of epigenetic imprinting biomarkers in thyroid nodules. PATIENTS AND METHODS: A total of 550 patients with fine-needle aspiration (FNA)-evaluated and histopathologically confirmed thyroid nodules were consecutively recruited from eight medical centers.
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Tran, Phuoc T. MD, PhD 1,2,3,4,; Lowe, Kathryn BS 1; Tsai, Hua-Ling PhD 2; Song, Daniel Y. MD 1,2,3,; Hung, Arthur Y. MD 5,; Hearn, Jason W.D. MD 6,; Miller, Steven MD 7; Proudfoot, James A. PhD 8,; Deek, Matthew P. MD 1; Phillips, Ryan MD, PhD 1,; Lotan, Tamara MD 9,; Paller, Channing J. MD 2,3,; Marshall, Catherine H. MD 2,; Markowski, Mark MD, PhD 2,; Dipasquale, Shirl BSN 1; Denmeade, Samuel MD 2,3,; Carducci, Michael MD 2,3,; Eisenberger, Mario MD 2,3,; DeWeese, Theodore L. MD 1,2,3,; Orton, Matthew MD 10; Deville, Curtiland MD 1,; Davicioni, Elai PhD 8,; Liauw, Stanley L. MD 11; Heath, Elisabeth I. MD 7,; Greco, Stephen MD 1; Desai, Neil B. MD 12,; Spratt, Daniel E. MD 13,; Feng, Felix MD 14,; Wang, Hao PhD, MS 2; Beer, Tomasz M. MD 15,; Antonarakis, Emmanuel S. MD 2,16,,
doi : 10.1200/JCO.22.01662
We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men with recurrent prostate cancer after radical prostatectomy (RP).
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Moy, Beverly MD, MPH 1; Rumble, R. Bryan MSc 2; Carey, Lisa A. MD, ScM 3; for the Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer Expert Panel
doi : 10.1200/JCO.22.02807
AB ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. (C) 2023 American Society of Clinical Oncology
Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
McCaw, Zachary R. PhD; Ludmir, Ethan B. MD; Wei, Lee-Jen PhD
doi : 10.1200/JCO.22.01759
Reply to Z.R. McCaw et al.
Rugo, Hope S. MD; Umanzor, Gerardo A. MD; Kwan, Min-Fun R. MBBS, MRCP; Cutler, David L. MD
doi : 10.1200/JCO.22.02157
Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.
Mangla, Ankit MD
doi : 10.1200/JCO.22.01903
Risk of Overusing Sentinel Node Biopsy in Patients With Thin Melanoma.
Hindie, Elif MD, PhD
doi : 10.1200/JCO.22.01963
Reply to A. Mangla and E. Hindie.
Moncrieff, Marc D. MD; Sondak, Vernon K. MD; Thompson, John F. MD; Zager, Jonathan S. MD
doi : 10.1200/JCO.22.02218
